Diabetes
-
HCCI Spotlights National Diabetes Month: ESI Enrollees with Diabetes Face High Out-of-Pocket Costs. A Cap on Insulin Costs Would Help Many.
Read more: HCCI Spotlights National Diabetes Month: ESI Enrollees with Diabetes Face High Out-of-Pocket Costs. A Cap on Insulin Costs Would Help Many.Diabetes is a chronic health condition that affects over 10% of the U.S. population. It is possible for people who are diagnosed with diabetes to live a healthy, long life if the condition is managed properly. However, management often involves significant health care use, which can be costly for patients. Over the past few months, we used HCCI’s…
-
Over 50% of Insulin Users with ESI Spend over $35 Out-of-pocket on 30-day Supply of Insulin
Read more: Over 50% of Insulin Users with ESI Spend over $35 Out-of-pocket on 30-day Supply of InsulinPreviously, HCCI analyzed prescription drug spending to understand how many insulin users with employer sponsored insurance (ESI) would be affected by a $35 monthly cap on patient out-of-pocket spending on insulin. Our estimates were based on average monthly out-of-pocket spending on insulin across all insulin products. The Inflation Reduction Act (IRA) recently passed by Congress…
-
Privately Insured Individuals with Diabetes Spend Twice as Much Out-of-Pocket on Health Care as those without Diabetes
Read more: Privately Insured Individuals with Diabetes Spend Twice as Much Out-of-Pocket on Health Care as those without DiabetesOver 10% of the U.S. population— more than 34 million individuals— lives with diabetes, with 1.5 million new cases diagnosed each year. As people with diabetes manage this chronic condition, they often pay substantial amounts out of their own pockets on medical care and prescription medications. Using HCCI’s unique health care claims dataset, this brief…
-
Insulin Use Explains Variation in Level, but not Growth, of Out-of-Pocket Spending on Insulin Products
Read more: Insulin Use Explains Variation in Level, but not Growth, of Out-of-Pocket Spending on Insulin ProductsWe previously published two blogs discussing trends in out-of-pocket spending on insulin products. First, we presented data illustrating how average monthly out-of-pocket spending in 2017 varied considerably by month, particularly for individuals enrolled in consumer-directed health plans (CDHPs) that carry higher deductibles. Second, we examined the relationship between increasing point-of-sale prices between 2012 and 2017…
-
Rising Point-of-Sale Prices for Insulin Correspond with Higher Out-of-Pocket Spending on Insulin in January
Read more: Rising Point-of-Sale Prices for Insulin Correspond with Higher Out-of-Pocket Spending on Insulin in JanuaryEarlier this week we presented data on out-of-pocket spending on insulin during each month in 2017. In that blog, we showed that enrollees in employer-sponsored health insurance paid more out-of-pocket for insulin products at the beginning of the calendar year. We examined the relationship between increasing point-of-sale prices for insulin and higher out-of-pocket spending in…
-
Out-of-Pocket Spending on Insulin is Highest at the Beginning of the Year
Tags: Commercially Insured, Consumer-Directed Health Plans, Diabetes, Drug Spending, Geographic Variation, Insulin
Read more: Out-of-Pocket Spending on Insulin is Highest at the Beginning of the YearPeople who get health insurance through their jobs pay more than twice as much for insulin at the beginning of the year than they do at the end of the year, on average. New analysis of HCCI data shows that, nationally, in January 2017, average out-of-pocket spending on insulin was $105. This spending declined every…
-
CNBC: Eli Lilly Confirms Probe by New York’s Attorney General over Insulin Prices
Read more: CNBC: Eli Lilly Confirms Probe by New York’s Attorney General over Insulin PricesHCCI’s research on insulin prices was mentioned in a CNBC report. From the article: “The Centers for Disease Control and Prevention estimates more than 30 million Americans have diabetes. The annual cost of insulin for people with Type 1 diabetes in the U.S. nearly doubled from 2012 to 2016 to $5,700 from $2,900, according to an analysis…
-
HCCI will be presenting at AcademyHealth’s 2019 Annual Research Meeting
Read more: HCCI will be presenting at AcademyHealth’s 2019 Annual Research MeetingThe Health Care Cost Institute (HCCI) is proud to present five posters at the AcademyHealth 2019 Annual Research Meeting in Washington, D.C. These posters, which cover HCCI research on a wide variety of topics, focus on health care spending and utilization trends among the commercially insured population. If you are attending the conference, please check…
-
The New York Times: Express Scripts Offers Diabetes Patients a $25 Cap for Monthly Insulin
Read more: The New York Times: Express Scripts Offers Diabetes Patients a $25 Cap for Monthly InsulinHCCI’s research on rising insulin list prices was recently cited by The New York Times in its reporting on Express Scripts’ new plan to offer a $25 cap for month insulin. From the article: “Consumers whose drug benefits are managed by Express Scripts could see their out-of-pocket costs for insulin limited to $25 a month…
-
HCCI Research Used in Support of Congressional Inquiries
Read more: HCCI Research Used in Support of Congressional InquiriesHCCI’s recent report on rising insulin prices was cited in support of congressional inquiries into drug pricing. This included a letter from U.S. Senator Tim Kaine (D-VA) to executives at Eli Lilly, Novo Nordisk, and Sanofi requesting information on insulin pricing. Additionally, HCCI’s research on emergency care was cited in a letter from U.S. Senators Bill Cassidy…